Ono Pharmaceutical Co Ltd ADR OPHLY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.87
- Day Range
- $4.98–5.01
- 52-Week Range
- $3.55–5.75
- Bid/Ask
- $4.98 / $5.00
- Shares Outstanding
- 1.41B
- Market Cap
- $7.04B
- Volume/Avg
- 24,945 / 37,490
Key Statistics
- Price/Earnings (Normalized)
- 14.84
- Price/Sales
- 2.01
- Dividend Yield (Trailing)
- 3.45%
- Dividend Yield (Forward)
- 3.45%
- Total Yield
- 3.45%
Company Profile
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,287
- Website
- https://www.ono-pharma.com
Valuation
|
Metric
|
OPHLY
|
|---|---|
Price/Earnings (Normalized) | 14.84 |
Price/Book Value | 1.28 |
Price/Sales | 2.01 |
Price/Cash Flow | 7.61 |
Price/Earnings
OPHLY
Financial Strength
|
Metric
|
OPHLY
|
|---|---|
Quick Ratio | 2.35 |
Current Ratio | 2.86 |
Interest Coverage | 26.06 |
Quick Ratio
OPHLY
Profitability
|
Metric
|
OPHLY
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
OPHLY
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|hCHvdkJ | LOCK|@? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|v@KWkLf | LOCK|&>y | $621B | |||
| AbbVie Inc
ABBV
| LOCK|FTBfq?@ | LOCK|@L | $435B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|nqR>w@W | LOCK|r$ | $360B | |||
| Merck & Co Inc
MRK
| LOCK|M$v^%g | LOCK|cG | $317B | |||
| Novartis AG ADR
NVS
| LOCK|?>D!cD^q | LOCK|jW | $292B | |||
| AstraZeneca PLC
AZN
| LOCK|BH#WM$K | LOCK|?&W | $251B | |||
| Amgen Inc
AMGN
| LOCK|D%&^&&M^ | LOCK|$% | $220B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|<C$V#C | LOCK|&F | $201B | |||
| Gilead Sciences Inc
GILD
| LOCK|##nV$<q | LOCK|fzS | $162B |
United States